Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

THE TRUTH ABOUT: 2 - Caught on Camera

‘When I was a child, everyone used it’: woman blames Johnson & Johnson talc for her cancer

Sue Rizzello is among thousands in UK suing the firm, which denies selling baby powder containing asbestos

The Guardian - UK

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

Benzinga

Johnson & Johnson faces UK lawsuit over cancer claims

IN FULL

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Thousands sue Johnson & Johnson in UK over baby powder cancer claims

The pharmaceutical company has been accused of ‘concealing’ the risk to the public for decades

The Independent UK

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Barchart

AI came from tech, but the most advanced AI businesses are in every industry

Fortune’s AIQ 50 list of the most “mature” AI companies shows how different businesses are taking advantage of AI to meet their needs.

Fortune

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Tylenol maker Kenvue blasts Trump administration's autism claim

The over-the-counter drug is a critical product for Kenvue.

Axios

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

Benzinga

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Barchart

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

“Impressive value for guitarists seeking rich clean/overdrive tones and timeless distortion tones”: PRS Archon Classic Head review

The PRS Archon Classic runs the gamut from crystal cleans to classic crunch and hot-rodded high gain

Guitar World

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Barchart

Stock Of The Day: Breakout In Johnson & Johnson

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

The company will likely focus on off-loading smaller beauty brands.

Barchart

6 Stocks to Buy to Give Your Portfolio the Perfect Mix of Growth, Value, and Defense

This blend of stocks may be the key to long-term success.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

Barchart

J&J Snack Foods Hits New 52-Week Low: Time to Buy?

Among the 96 Nasdaq stocks hitting new 52-week lows Tuesday was the New Jersey-based manufacturer of snack foods and frozen beverages. The small-cap stock hit its 10th new 52-week low over the past 12 months. Time to buy?

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

UnitedHealth spent $1.7 million on executive security last year, 4 times the corporate average. Experts expect the figure to keep climbing

UnitedHealth Group reported its executive security compensation months after the CEO of health insurance arm UnitedHealthcare was fatally shot in December.

Barchart

3 Dividend Stocks to Buy for a Safe Haven in This Volatile Market

The consistency in their dividend payments makes them dependable stocks in a volatile market.

The Independent UK

Johnson & Johnson begins battle over baby powder’s ‘link to cancer’ in $10 billion case

Courts have rejected J&J’s two previous efforts to resolve the talc litigation

Barchart

Slush Puppie’s Parent Hits 52-Week Low. Time to Buy?

J&J Snack Foods, the maker of food and beverage brands such as Slush Puppie, SuperPretzel, and Hola Churros, hit a 52-week low on Tuesday, its 14th in the past 12 months. Here’s why it’s time to buy.

The Guardian - UK

Thousands to sue Johnson & Johnson in UK over alleged talc link to cancer

Group action with 3,500 claimants alleges company knew its talcum powder products contained dangerous asbestos

Barchart

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Fortune

How tech leaders are rethinking their cloud strategies in the face of fast-rising costs

As spending on cloud computing rises sharply amid the generative AI boom, executives are on the hunt for cost savings.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.